Jiangsu Vcare Pharmaceutical Technology Co., Ltd

This phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…

This phase III trial tests whether vicagrel, an experimental antiplatelet drug, can prevent major heart-related events better than the standard drug clopidogrel in people with acute coronary syndrome (such as a heart attack or unstable angina) who are undergoing a stent procedure…

This phase 3 trial tests whether an experimental oral drug called VC005 can reduce eczema symptoms in adults with moderate to severe atopic dermatitis. Participants are randomly assigned to receive either a low or high dose of VC005 or a placebo. The main goal is to see if more p…

This study tests a new cream called VC005 for people aged 12 and older with mild to moderate atopic dermatitis (eczema). The goal is to see if the cream can clear or nearly clear the skin rash better than a cream without medicine. About 360 participants will use either the study …

This phase 3 trial tests whether VC005 tablets can reduce symptoms of active ankylosing spondylitis, a type of arthritis that mainly affects the spine. About 420 adults aged 18 to 70 will receive either VC005 or a placebo for 48 weeks. The main goal is to see how many achieve a 2…

This study tests a new drug called VC005 in 120 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants will take either VC005 or a placebo daily for 52 weeks. The main goal is to see if the drug can reduce the size of white patches on …

This study tests a gel called VC005 on adults with mild to moderate atopic dermatitis (eczema). About 120 participants will use either the gel or a placebo to see if it safely reduces skin redness, itching, and rash. The goal is to ease symptoms, not cure the condition.

This early-stage study looks at how a single 25 mg dose of VC005 tablets behaves in people with mild or moderate liver impairment compared to healthy volunteers. The goal is to measure drug levels and safety. 24 participants will take one dose and be monitored closely.

This early-stage study looks at how a single dose of VC005 tablets is processed in people with kidney impairment compared to those with normal kidney function. Researchers will measure drug levels in the blood and check safety. The goal is to understand if kidney problems affect …